A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Roche logo

Roche

Status and phase

Completed
Phase 3

Conditions

Cytomegalovirus Retinitis
HIV Infections

Treatments

Drug: Ganciclovir
Drug: Valganciclovir

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002377
WV15376

Details and patient eligibility

About

To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.

Sex

All

Ages

14+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Documented AIDS diagnosis
  • Newly diagnosed peripheral CMV retinitis
  • More than 3 weeks of previous therapy for CMV retinitis

Trial contacts and locations

19

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems